This note demonstrates how using HTRF to quantify human IFNγ is a powerful and effective approach for the functional characterization of anti-PD1/PDL1 antibodies. Complementary to a real-time live-cell imaging approach, the HTRF-based IFNγ assay delivers fast and accurate results, boosting immuno-oncology drug discovery programs.